Patient and family resources
We are developing novel cell therapies to transform all aspects of bone marrow transplant.
Orca Bio is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. We put the needs of patients, families and healthcare providers at the center of everything we do and decisions we make.
We founded Orca Bio on the belief that there is a more effective and compassionate way to target blood cancer and decrease transplant related mortalities. Orca Bio is working comprehensively across the transplant journey to change this reality.
Our Clinical Studies
We founded Orca Bio on the belief that there is a more effective and compassionate way to target cancer and improve transplant related mortalities. The company is momentarily conducting a large multi-center Phase 1 study for its most recent clinical-stage program, OGFT-001, a fully engineered donor graft derived from mobilized peripheral blood.
The company’s most advanced clinical-stage program is TRGFT-201, a partially engineered and enriched donor graft for recipients undergoing allogeneic HSCTs for hematologic malignancies, currently investigated as part of a Phase 2 study.